Hua

Whakaahuatanga:
Ko te prim-o-glucosylcimifugin he kaha nga paanga anti-inflammatory.Ko te korero o te iNOS me te COX-2 ka taea te aukati ma te whakahaere i te tohu JAK2 / STAT3 transd.

Ngā kāwai hāngai:
Te ara tohu > > mate mate me te mumura > > nitric oxide synthase
Te mara rangahau > > te mumura / mate mate
Hua Taiao > > etahi atu

Whāinga:iNOS
COX-2

Akoranga In Vitro:
prim-o-glucosylglycine (POG) Ko te ihirangi teitei o te chromone me tetahi o nga waahanga kaha matua i roto i te Fangfeng (RS).Ko te Prim-o-glucosylglycine he mahi anti-inflammatory i roto i nga macrophages raw 264.7 ma te aukati i te whakawhiti tohu JAK2 / STAT3 me te aukati i te whakahuatanga o te iNOS me te COX-2.Ko te cytotoxicity o te prim-o-glucoside i runga i te LPS kua whakahohea te mata 264.7 macrophages i ine.Whakamahia te LPS (1 μ G / ml) me te whakanui ake i nga kohinga o te prim-o-glucosylglycine (15, 50 me 100 μ G / ml) mo nga haora 24, ka arotakehia te oranga o te pūtau e te CCK-8 assay.Ka whakatauritea ki nga pūtau (mana) i rongoahia e DMSO, 24 haora me te rongo ki te 15-100 μ I muri i te g / ml prim-o-glucoside, kaore i tino pa te oranga o te pūtau.Hei ako i te huanga anti-inflammatory o te prim-o-glucosylglycine, mena ka pa te prim-o-glucosylglycine ki te NO synthesis i tirohia i roto i nga pūtau 264.7 raw LPS kua whakahohehia.Whakamahia te LPS (1 μ G / ml) me nga momo kukū o prim-o-glucosylglycine (15, 50 me 100 μ G / ml) mo te 24 haora.Kaore i ine te kukū i roto i te supernatant ahurea na te tauhohenga a Griess.Ko te kukū o te kore i roto i te supernatant ahurea i tino piki ake me te whakakitenga o te LPS, a ko te prim-o-glucoside i tino aukati i te LPS i kore ai e hanga i runga i te kukūtanga ti'aturi [1].
I Vivo Akoranga
Ko te wai horoi horoi bronchoalveolar (BALF) i kohia i nga haora 7 i muri i te whakahaeretanga o te lipopolysaccharide (LPS), me te taumata cytokine i roto i te BALF i inehia e ELISA.Ka whakatauritea ki te roopu whakahaere, TNF i roto i te BALF-α， IL-1 β Me nga taumata IL-6 i tino piki ake.Engari, ko te maimoatanga o mua me te prime-o-glucosylglycine (2.5, 5, 10 mg / kg) ka tino whakahekehia te TNF-α， IL-1 β me te IL-6 i roto i te tikanga horopeta-ti'aturi (P <0.05, P <0.05, 0.01). ) [1].

Whakamatau Pūtau
I whakamahia te Kete tatau tatau (CCK-8) hei whakatau i te kukū cytotoxic o te prim-o-glucosylglycine.I te poto, 264.7 nga pūtau mata i tukuna ki te 1 mo ia puna × Ko te kiato o nga pūtau 104 i werohia ki roto i nga puna 96 ka whakakororia i te po.Na ka whakamahi i te 1 μ I whakaihiihihia nga pūtau ki te g / ml LPS me te rongoa ki nga momo kukū o te prim-o-glucosylglycine (15, 50 me te 100 μ g / mL; Medchem express, Princeton, NJ, USA) maimoatanga DMSO ranei.Whai muri i te hekitanga i te 37 ℃ mo te 24 haora, ka taapirihia te otinga CCK-8 ki ia puna ka whakakororia mo tetahi atu haora.I ine te absorbance i te 450 nm ma te whakamahi i te panui microplate [1].

Whakamatau Kararehe
kiore [1] BALB / C kiore tane, 8 wiki te pakeke, 18 ki te 20 karamu te taumaha.I wehea matapōkeretia ngā kiore kia 5 ngā rōpū: rōpū whakahaere;Rōpū LPS;LPS + prime-o-glucosylglycine (2.5, 5, 10mg / kg taumaha tinana).Ko te Prime-o-glucosylglycine i tukuna i roto i te waahi.I muri i te 1 haora, ko nga kiore i roto i te roopu LPS me te roopu LPS + prime-o-glucosylglycine i whakawhiwhia ki te 50 mg / L intranasal (i roto i) (200 mg / L) μ LLPs ki te whakaoho i te whara o te huhu.Ko nga kiore mana i whakawhiwhia ki te 50% intranasal (i roto) kaore he LPS μ LPBS
[1]

Tohutoro:
[1].Zhou J, et al.Ko te Prim-O-glucosylcimifugin ka whakakorikori i te Whakautu Huka a Lipopolysaccharide i roto i te RAW 264.7 Macrophages.Pharmacogn Mag.2017 Hūrae-Sep;13(51):378-384.
[2].Chen N, et al.Ko te Pirimia-O-glucosylcimifugin te whakaheke i te lipopolysaccharide-induced acute lung injury i roto i nga kiore.Int Immunopharmacol.2013 Hune;16(2):139-47.